After hanging out the for sale sign and filing for bankruptcy earlier this year, the genetic testing provider Invitae has found a new home for its portfolio at Labcorp. The two companies announced ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Bull case: Invitae has launched a plan to reach positive cash flow as soon as possible. Any progress could drive share gains. Bear case: Invitae comes with too much risk in an uncertain market. Could ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae is boosting its neurology and cardiology diagnostic test offerings. The San Francisco-based company will be adding 11 panels for heritable diseases and will update 17 existing neurology panels ...

Invitae Corporation (NYSE:NVTA) shares are trading lower this Wednesday after the company reported fourth-quarter financial results and provided guidance for full-year 2023. The company also announced ...

Genetic testing company Invitae has made more than a dozen acquisitions to further its goal of democratizing genetic testing. Its latest deal, a $325 million bid to acquire Ciitizen, will add patients ...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will ...

Medical genetics firm Invitae (NYSE:NVTA) suffered a shocking fall from grace as insider reports point to an upcoming bankruptcy filing. Although the company forwarded a compelling concept — ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...